Temozolomide Acid

CAS No. 113942-30-6

Temozolomide Acid( TMZA )

Catalog No. M22721 CAS No. 113942-30-6

Temozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 35 In Stock
100MG 50 In Stock
200MG 72 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Temozolomide Acid
  • Note
    Research use only, not for human use.
  • Brief Description
    Temozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.
  • Description
    Temozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    TMZA
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    113942-30-6
  • Formula Weight
    195.14
  • Molecular Formula
    C6H5N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:Soluble; Water:Insoluble
  • SMILES
    Cn1nnc2c(ncn2c1=O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee S Y . Temozolomide resistance in glioblastoma multiforme[J]. Genes & Diseases, 2016, 3( 3):198-210.
molnova catalog
related products
  • Melittoside

    Melittoside is a natural product and may have antioxidant activity.

  • SAH

    SAH is an inhibitor for the METTL3-METTL14 heterodimer complex (METTL3-14 IC50: 0.9 μM).

  • NFATc1-IN-1

    NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM.